Promising Options Emerging for Treating Metastatic ER+ Breast Cancer
Integration of newer targeted agents into combination therapies will necessitate the development of predictive biomarkers.
SABCS 2016
Everolimus Improves Fulvestrant Benefits in AI-Resistant Metastatic Breast Cancer
Adding everolimus to fulvestrant improves progression-free survival (PFS) among postmenopausal women.
The Current State of HER2+ Breast Cancer Management
Many agents are in ongoing trials, and may provide additional options for patients with metastatic HER2-positive disease.
Treating Older Patients With Breast Cancer: Still a Challenge
Lack of research data and failure to consider patients’ functional age affects how older adults with breast cancer are managed.
Clinically Important Factors Identified for Trastuzumab Response in HER2-positive Patients
Genetics, RNA subtype, and tumor microenvironment are clinically important and independently predictive of trastuzumab response.
Breast Cancers With PIK3CA Mutations May Derive Greater Benefit From Letrozole
Postmenopausal women with ER-positive, HER2-negative breast cancer with PIK3CA mutations may derive greater benefit from letrozole.
Novel BRD4 Inhibitor Enhances Endocrine Therapy Efficacy in ER+ Breast Cancer Models
The novel bromodomain-containing protein 4 (BRD4) inhibitor GS-6510 demonstrated anti-tumor activity.
Radioactive Seed Localization Recommended in Non-palpable Breast Cancer
Radioactive seed localization (RSL) may be preferable to wire guided localization (WGL) for the resection of non-palpable invasive breast cancer.
TILs Strongly Predictive of Response to Neoadjuvant Chemo in Breast Cancer
Tumor-infiltrating lymphocytes (TILs) appear to be strongly predictive of response to neoadjuvant chemotherapy in all molecular subtypes of breast cancer.
TILs Linked to Reduced Intratumor Heterogeneity in Triple Negative Breast Cancer
A high level of tumor-infiltrating lymphocytes (TILs) is associated with reduced intratumor heterogeneity in triple negative breast cancer (TNBC).
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in SABCS 2016
Loading... 
Loading...